Search

Copyright of Turkiye Klinikleri Journal of Nursing Sciences is the property of Turkiye Klinikleri and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: The study retrospectively evaluated the effects of quetiapine on sleep in primary insomnia and neurodegenerative diseases using polysomnographic data. Materials and Methods: Between January 1, 2010, and June 1, 2023, the records of 49 patients who were followed up in the sleep outpatient clinic of the neurology department of our hospital and who underwent polysomnography examination were retrospectively reviewed. Patients aged between 18 and 65 years with primary insomnia and neurodegenerative diseases were included in the study. Results: The mean age of 49 patients (26 females and 23 males) were 56.67 years. The mean quetiapine dose was 59.37. Sleep latency, stage 1 (N1) duration, stage 2 (N2) duration, mean and minimum SO2 and apnea-hypopnea index were similar. Total sleep duration, stage 3 (N3) duration and rapid eye movement (REM) sleep duration were higher in neurodegenerative patients. N3 duration was shorter in patients with primary insomnia on quetiapine. Sleep duration and REM duration were longer in the neurodegenerative group and sleep latency was longer in primary insomnia in quetiapine users. Among quetiapine users, the N2 sleep percentage was higher and the nonREM 3 sleep percentage was lower in primary insomnia, whereas there was no difference in sleep percentages in neurodegenerative patients. Conclusion: Quetiapine is an atypical antipsychotic agent. It shortens sleep latency and decreases the percentage of REM sleep and wake time. It increases total sleep time, sleep efficiency, and N2 sleep. In this study, in primary insomnia patients using quetiapine, N3 sleep duration was shorter and sleep percentage was lower, whereas N2 sleep percentage was longer. There has been no placebo-controlled study of any antipsychotic drug for treating insomnia. [ABSTRACT FROM AUTHOR]

Objective: We evaluated and compare sleep quality and disorders according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) A, B, C, D groups in patients with Chronic Obstructive Pulmonary Disease (COPD) and to determine sleep disorders. Materials and Methods: Our study included 94 patients who applied to Pamukkale University Medical Faculty Hospital Chest Diseases Polyclinic between January 2016 and January 2017, were diagnosed with COPD according to GOLD criteria, were not in a COPD attack at the time of admission and agreed to participate in the study. Results: In patients with COPD, as the severity of stages increased, a decrease in mean FEV1 values was detected and as the FEV1 values decreased, the mean oxygen values measured during the night decreased. According to the GOLD stage, there was no significant difference between total sleep periods, sleep activity, sleep latency, rapid eye movement (REM) sleep duration, and non-REM sleep duration. According to polysomnography results, apnea-hypopnea index (AHI) was found to be below 5 in 40% of the patients. There was no statistically significant difference between the AHI and COPD stages (p=0.581). Conclusion: No significant difference was found between the COPD stage and AHI severity. However, as COPD stages increased, a decrease in mean nocturnal oxygen saturation was detected. Nocturnal oxygen desaturation is the main cause of comorbidities observed in patients COPD. As a result, careful attention should be given to night desaturation in advanced patients with COPD, and the necessary procedures must be performed to prevent comorbidities. [ABSTRACT FROM AUTHOR]

Aim:Our objective is to evaluate the sleep quality in adolescents in relation to age and sleep-related habitual and environmental factors.Materials and Methods:A total of 150 adolescents aged 12-20 years [mean (standard deviation) age: 15.5 (1.9) years; 65.3% were female] were included on a voluntary basis in this cross-sectional questionnaire survey. The questionnaire form included items on subject demographics (age, gender), before sleep activities (tea/coffee consumption, reading, use of social media), presence and of electronic devices (computer, television, cell phone) in the bedroom and presence of roommate, as well as items on Pittsburgh Sleep Quality Index (PSQI).Results:Usual bedtime between 23.00-24.00 p.m. (38.0%), sleep latency of 15 minutes (38.0%), sleep duration of ≥7 hours (79.0%) and usual wake up time between 6.00-7.00 am (41.7%) were the most commonly identified sleeping patterns. PSQI total scores revealed poor sleep quality (scores ≥5) in 82.0% of participants, while 40.0% of participants rated their sleep quality to be poor. Later bedtime (≥24.00) was more likely in late-adolescents (64.7%) than earlier age groups (p=0.009). Sleep latency >30 minutes, difficulty in breathing and bad dreams during sleep, presence of electronic device in the bedroom and use of social media before sleep and difficulty in performing daily activities were associated with higher likelihood of PSQI-based poor sleep quality (p5) in 82.0% of adolescents, regardless of adolescence period, and association sleep latency >30 minutes, difficulty in breathing and bad dreams during sleep, presence of electronic device in the bedroom and use of social media near bedtime with higher likelihood PSQI-based poor sleep quality.